Syndax Pharmaceuticals, Inc.
SNDX
$13.33
$0.030.23%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 44.30% | 163.77% | 366.83% | -- | -- |
| Gross Profit | -26.33% | -139.63% | -355.57% | -- | -- |
| SG&A Expenses | 80.63% | 95.03% | 103.35% | 103.17% | 101.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.01% | 73.75% | 68.62% | 63.72% | 51.53% |
| Operating Income | -47.71% | -65.50% | -66.60% | -63.72% | -51.53% |
| Income Before Tax | -52.25% | -68.71% | -64.70% | -56.97% | -40.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.25% | -68.71% | -64.70% | -56.97% | -40.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.25% | -68.71% | -64.70% | -56.97% | -40.19% |
| EBIT | -47.71% | -65.50% | -66.60% | -63.72% | -51.53% |
| EBITDA | -47.72% | -65.51% | -66.61% | -63.74% | -51.55% |
| EPS Basic | -25.83% | -40.47% | -38.68% | -33.10% | -20.58% |
| Normalized Basic EPS | -25.83% | -40.48% | -38.69% | -33.10% | -20.58% |
| EPS Diluted | -25.63% | -40.54% | -38.76% | -33.18% | -20.67% |
| Normalized Diluted EPS | -25.83% | -40.48% | -38.69% | -33.10% | -20.58% |
| Average Basic Shares Outstanding | 21.41% | 20.70% | 18.99% | 17.27% | 15.83% |
| Average Diluted Shares Outstanding | 21.41% | 20.70% | 18.99% | 17.27% | 15.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |